<!DOCTYPE html>

<html lang="en" data-theme="light">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Cholinergic Transmission & Drugs - Essentials of Medical Pharmacology</title>

<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">

<link rel="stylesheet" href="../styles/main.css">

<script>
MathJax = {
    tex: {
        inlineMath: [['$', '$'], ['\\(', '\\)']],
        displayMath: [['$$', '$$'], ['\\[', '\\]']],
        processEscapes: true,
        processEnvironments: true
    },
    svg: { fontCache: 'global' },
    options: {
        skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
    }
};
</script>
<script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
<a href="#main-content" class="skip-link">Skip to main content</a>

<button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
    <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
    <span class="theme-toggle-icon dark-icon">üåô</span>
</button>

<div class="reading-progress-container">
    <div class="reading-progress-bar" id="reading-progress"></div>
</div>

<!-- Floating TOC -->
<nav class="floating-toc" id="floating-toc">
    <div class="floating-toc-header">
        <span>üìë</span> Table of Contents
    </div>
    <ul class="floating-toc-list">
        <li><a href="#transmission">Cholinergic Transmission</a></li>
        <li><a href="#receptors">Cholinoceptors</a></li>
        <li><a href="#agonists">Cholinergic Drugs (Agonists)</a></li>
        <li><a href="#anticholinesterases">Anticholinesterases</a></li>
        <li><a href="#uses">Therapeutic Uses</a></li>
        <li><a href="#poisoning">Anti-ChE Poisoning</a></li>
        <li><a href="#problem-study">Problem Directed Study</a></li>
    </ul>
</nav>

<div class="page-wrapper">
    <div class="container">
        <article class="document-article">
            <header class="document-header">
                <div class="header-badge">
                    <span>üíä</span>
                    <span>Topic 08</span>
                </div>
                <h1 class="document-title">Cholinergic Transmission and Cholinergic Drugs</h1>
                <div class="title-meta">
                    <div class="meta-item">
                        <span>üìö</span>
                        <span>Drugs Acting on ANS</span>
                    </div>
                    <div class="meta-item">
                        <span>‚è±Ô∏è</span>
                        <span>40 min read</span>
                    </div>
                </div>
            </header>

            <main id="main-content" class="content-wrapper">
                <!-- Section 1: Cholinergic Transmission -->
                <section class="content-section" id="transmission">
                    <div class="section-header">
                        <div class="section-number">01</div>
                        <h2 class="section-title">
                            <span class="title-icon">‚ö°</span>
                            Cholinergic Transmission
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Acetylcholine (ACh) is a major neurohumoral transmitter at autonomic, somatic as well as central sites. It is synthesized locally in the cholinergic nerve endings.</p>
                        
                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../../../../../assets/images/image-20251214-a37fba2b.jpeg" alt="Cholinergic neuronal mechanisms" class="figure-image">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 7.1: Cholinergic neuronal mechanisms showing synthesis, storage, release, and action of ACh.</figcaption>
                        </figure>

                        <h3>Key Steps & Interferences</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">1</span>
                                <span class="list-content"><strong>Synthesis:</strong> Choline is actively taken up by the axonal membrane ($\mathrm{Na}^{+}$:choline cotransporter). Acetylation occurs via <em>choline acetyl transferase</em> (ChAT). <strong>Hemicholinium (HC3)</strong> blocks choline uptake (rate limiting step).</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">2</span>
                                <span class="list-content"><strong>Storage:</strong> ACh is stored in synaptic vesicles via vesicle associated transporter (VAT). <strong>Vesamicol</strong> blocks this uptake.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">3</span>
                                <span class="list-content"><strong>Release:</strong> Occurs by exocytosis triggered by nerve impulse. <strong>Botulinum toxin</strong> inhibits release; <strong>Black widow spider toxin</strong> induces massive release and depletion.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">4</span>
                                <span class="list-content"><strong>Destruction:</strong> Rapidly hydrolysed by Cholinesterase (ChE) to choline and acetic acid.</span>
                            </li>
                        </ul>

                        <div class="callout callout--warning">
                            <div class="callout-header">
                                <span class="callout-icon">‚ò†Ô∏è</span>
                                <h4 class="callout-title">Botulinum Toxin</h4>
                            </div>
                            <div class="callout-content">
                                <p>Botulinum toxin A (BOTOX) causes long-lasting loss of cholinergic transmission. It is used to treat spastic neurological conditions (blepharospasm, cerebral palsy, strabismus) and for cosmetic removal of facial wrinkles.</p>
                            </div>
                        </div>

                        <h3>Cholinesterases</h3>
                        <p>There are two types of enzymes that hydrolyse acetylcholine:</p>
                        <div class="table-responsive">
                            <table class="comparison-table">
                                <thead>
                                    <tr>
                                        <th>Feature</th>
                                        <th>Acetylcholinesterase (True)</th>
                                        <th>Butyrylcholinesterase (Pseudo)</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td><strong>Distribution</strong></td>
                                        <td>Cholinergic sites, RBC, gray matter</td>
                                        <td>Plasma, liver, intestine, white matter</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Hydrolysis of ACh</strong></td>
                                        <td>Very fast</td>
                                        <td>Slow</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Methacholine</strong></td>
                                        <td>Hydrolysed (slower than ACh)</td>
                                        <td>Not hydrolysed</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Benzoylcholine</strong></td>
                                        <td>Not hydrolysed</td>
                                        <td>Hydrolysed</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Function</strong></td>
                                        <td>Termination of ACh action</td>
                                        <td>Hydrolysis of ingested esters</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>

                <!-- Section 2: Cholinoceptors -->
                <section class="content-section" id="receptors">
                    <div class="section-header">
                        <div class="section-number">02</div>
                        <h2 class="section-title">
                            <span class="title-icon">üì°</span>
                            Cholinoceptors
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Two classes of receptors for ACh are recognised: <strong>Muscarinic</strong> and <strong>Nicotinic</strong>.</p>

                        <h3>1. Muscarinic Receptors (G-protein coupled)</h3>
                        <p>Selectively stimulated by muscarine and blocked by atropine.</p>
                        
                        <div class="table-responsive">
                            <table class="comparison-table">
                                <thead>
                                    <tr>
                                        <th>Subtype</th>
                                        <th>Location</th>
                                        <th>Function</th>
                                        <th>Mechanism</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td><strong>$M_1$</strong></td>
                                        <td>Autonomic ganglia, Gastric glands, CNS</td>
                                        <td>Depolarization, Acid secretion, Learning/Memory</td>
                                        <td>Gq (‚Üë $IP_3$/DAG, ‚Üë $Ca^{2+}$)</td>
                                    </tr>
                                    <tr>
                                        <td><strong>$M_2$</strong></td>
                                        <td>Heart (SA/AV node, Atria), Nerve endings</td>
                                        <td>Hyperpolarization, ‚Üì HR, ‚Üì Conduction, ‚Üì ACh release</td>
                                        <td>Gi/Go (‚Üì cAMP, ‚Üë $K^+$ conductance)</td>
                                    </tr>
                                    <tr>
                                        <td><strong>$M_3$</strong></td>
                                        <td>Smooth muscles, Glands, Vascular endothelium</td>
                                        <td>Contraction (Visceral), Secretion, Vasodilatation (via NO)</td>
                                        <td>Gq (‚Üë $IP_3$/DAG, ‚Üë $Ca^{2+}$)</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3>2. Nicotinic Receptors (Ligand gated cation channels)</h3>
                        <p>Selectively stimulated by nicotine and blocked by tubocurarine or hexamethonium.</p>

                        <div class="table-responsive">
                            <table class="comparison-table">
                                <thead>
                                    <tr>
                                        <th>Subtype</th>
                                        <th>Location</th>
                                        <th>Agonist</th>
                                        <th>Antagonist</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td><strong>$N_M$</strong></td>
                                        <td>Neuromuscular junction</td>
                                        <td>PTMA</td>
                                        <td>Tubocurarine</td>
                                    </tr>
                                    <tr>
                                        <td><strong>$N_N$</strong></td>
                                        <td>Autonomic ganglia, Adrenal medulla, CNS</td>
                                        <td>DMPP</td>
                                        <td>Hexamethonium</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>

                <!-- Section 3: Cholinergic Drugs -->
                <section class="content-section" id="agonists">
                    <div class="section-header">
                        <div class="section-number">03</div>
                        <h2 class="section-title">
                            <span class="title-icon">üíä</span>
                            Cholinergic Agonists
                        </h2>
                    </div>

                    <div class="content-card">
                        <h3>A. Choline Esters</h3>
                        <p>Comparison of properties:</p>
                        <div class="table-responsive">
                            <table class="content-table">
                                <thead>
                                    <tr>
                                        <th>Drug</th>
                                        <th>ChE Susceptibility</th>
                                        <th>Muscarinic Action</th>
                                        <th>Nicotinic Action</th>
                                        <th>Use</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td><strong>Acetylcholine</strong></td>
                                        <td>High</td>
                                        <td>++</td>
                                        <td>++</td>
                                        <td>None (evanescent action)</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Methacholine</strong></td>
                                        <td>Low (AChE only)</td>
                                        <td>++ (CVS selective)</td>
                                        <td>¬±</td>
                                        <td>Rarely used</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Carbachol</strong></td>
                                        <td>Negligible</td>
                                        <td>+</td>
                                        <td>++</td>
                                        <td>Glaucoma</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Bethanechol</strong></td>
                                        <td>Negligible</td>
                                        <td>+ (GI/Bladder selective)</td>
                                        <td>-</td>
                                        <td>Urinary retention, Post-op ileus</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3>B. Natural Alkaloids</h3>
                        <ul class="enhanced-list">
                            <li class="list-item"><strong>Pilocarpine:</strong> From <em>Pilocarpus microphyllus</em>. Prominent muscarinic action. Used as miotic in glaucoma (0.5-4% drops) and as sialogogue.</li>
                            <li class="list-item"><strong>Muscarine:</strong> From <em>Amanita muscaria</em>. Toxicological importance only (Mushroom poisoning).</li>
                            <li class="list-item"><strong>Arecoline:</strong> From Betel nut. Nicotinic + Muscarinic actions. No therapeutic use.</li>
                        </ul>
                    </div>
                </section>

                <!-- Section 4: Anticholinesterases -->
                <section class="content-section" id="anticholinesterases">
                    <div class="section-header">
                        <div class="section-number">04</div>
                        <h2 class="section-title">
                            <span class="title-icon">üõë</span>
                            Anticholinesterases
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Agents which inhibit ChE, protect ACh from hydrolysis, and potentiate cholinergic effects. They act by reacting with the enzyme essentially in the same way as ACh.</p>

                        <h3>Classification</h3>
                        <div class="grid grid-2">
                            <div class="grid-item">
                                <h4>Reversible (Carbamates)</h4>
                                <ul>
                                    <li>Physostigmine</li>
                                    <li>Neostigmine</li>
                                    <li>Pyridostigmine</li>
                                    <li>Rivastigmine</li>
                                    <li>Donepezil</li>
                                    <li>Edrophonium (Non-carbamate, very short acting)</li>
                                </ul>
                            </div>
                            <div class="grid-item">
                                <h4>Irreversible (Organophosphates)</h4>
                                <ul>
                                    <li>Dyflos (DFP)</li>
                                    <li>Echothiophate</li>
                                    <li>Malathion, Parathion (Insecticides)</li>
                                    <li>Nerve gases (Tabun, Sarin)</li>
                                </ul>
                            </div>
                        </div>

                        <h3>Physostigmine vs Neostigmine</h3>
                        <div class="table-responsive">
                            <table class="comparison-table">
                                <thead>
                                    <tr>
                                        <th>Feature</th>
                                        <th>Physostigmine</th>
                                        <th>Neostigmine</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td><strong>Source</strong></td>
                                        <td>Natural (Calabar bean)</td>
                                        <td>Synthetic</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Chemistry</strong></td>
                                        <td>Tertiary amine (Lipid soluble)</td>
                                        <td>Quaternary ammonium (Lipid insoluble)</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Absorption</strong></td>
                                        <td>Good (Oral/Corneal)</td>
                                        <td>Poor</td>
                                    </tr>
                                    <tr>
                                        <td><strong>CNS Action</strong></td>
                                        <td>Present</td>
                                        <td>Absent</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Direct Action on $N_M$</strong></td>
                                        <td>Absent</td>
                                        <td>Present</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Main Uses</strong></td>
                                        <td>Glaucoma, Atropine poisoning</td>
                                        <td>Myasthenia gravis, Urinary retention, Curare reversal</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>

                <!-- Section 5: Therapeutic Uses -->
                <section class="content-section" id="uses">
                    <div class="section-header">
                        <div class="section-number">05</div>
                        <h2 class="section-title">
                            <span class="title-icon">üíâ</span>
                            Therapeutic Uses
                        </h2>
                    </div>

                    <div class="content-card">
                        <h4>1. Glaucoma</h4>
                        <p><strong>Pilocarpine</strong> is the preferred miotic (3rd line drug now). Increases tone of ciliary muscle and sphincter pupillae $\rightarrow$ improves aqueous outflow.</p>

                        <h4>2. Myasthenia Gravis</h4>
                        <p>Autoimmune disorder with antibodies against nicotinic receptors ($N_M$) at muscle endplate.</p>
                        <ul>
                            <li><strong>Diagnosis:</strong> Edrophonium test (Ameliorative test). Reverses weakness for short duration.</li>
                            <li><strong>Treatment:</strong> <strong>Neostigmine</strong> or <strong>Pyridostigmine</strong> (longer acting, less frequent dosing). Corticosteroids or immunosuppressants used in advanced cases.</li>
                        </ul>
                        
                        <div class="callout callout--warning">
                            <div class="callout-header">
                                <span class="callout-icon">‚ö†Ô∏è</span>
                                <h4 class="callout-title">Myasthenic vs Cholinergic Crisis</h4>
                            </div>
                            <div class="callout-content">
                                <p><strong>Myasthenic Crisis:</strong> Acute weakness due to disease exacerbation. Improves with Edrophonium.</p>
                                <p><strong>Cholinergic Crisis:</strong> Weakness due to overdose of anti-ChE (persistent depolarization). Worsens with Edrophonium.</p>
                            </div>
                        </div>

                        <h4>3. Postoperative Paralytic Ileus / Urinary Retention</h4>
                        <p><strong>Neostigmine</strong> or <strong>Bethanechol</strong>. Contraindicated if organic obstruction is present.</p>

                        <h4>4. Curare Reversal (Postoperative decurarization)</h4>
                        <p><strong>Neostigmine</strong> (0.5‚Äì2 mg i.v.) preceded by Atropine (to block muscarinic side effects) rapidly reverses muscle paralysis caused by competitive blockers.</p>

                        <h4>5. Belladonna Poisoning</h4>
                        <p><strong>Physostigmine</strong> (0.5‚Äì2 mg i.v.) is the specific antidote as it crosses BBB to antagonize central effects. Neostigmine is not effective against central toxicity.</p>

                        <h4>6. Alzheimer's Disease</h4>
                        <p>Brain cholinergic neurones are affected. Cerebroselective anti-ChEs like <strong>Rivastigmine</strong>, <strong>Donepezil</strong>, and <strong>Galantamine</strong> produce symptomatic improvement.</p>

                        <h4>7. Cobra Bite</h4>
                        <p>Neostigmine + Atropine prevent respiratory paralysis (neurotoxin has curare-like action).</p>
                    </div>
                </section>

                <!-- Section 6: Poisoning -->
                <section class="content-section" id="poisoning">
                    <div class="section-header">
                        <div class="section-number">06</div>
                        <h2 class="section-title">
                            <span class="title-icon">‚ò†Ô∏è</span>
                            Anticholinesterase Poisoning
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Common with agricultural organophosphate insecticides (accidental/suicidal).</p>
                        
                        <h3>Symptoms</h3>
                        <ul>
                            <li><strong>Muscarinic:</strong> Miosis, salivation, sweating, bronchospasm, colic, involuntary urination/defecation, hypotension, bradycardia.</li>
                            <li><strong>Nicotinic:</strong> Muscle fasciculations, weakness, respiratory paralysis.</li>
                            <li><strong>CNS:</strong> Confusion, ataxia, convulsions, coma.</li>
                        </ul>

                        <h3>Treatment</h3>
                        <ol class="enhanced-list">
                            <li class="list-item"><strong>Decontamination:</strong> Fresh air, wash skin/mucous membranes, gastric lavage.</li>
                            <li class="list-item"><strong>Supportive:</strong> Maintain airway, positive pressure respiration, maintain BP (diazepam for convulsions).</li>
                            <li class="list-item">
                                <strong>Specific Antidote: Atropine</strong>
                                <p>2 mg i.v. repeated every 10 min till signs of atropinization (dry mouth, dilated pupils) appear. Blocks muscarinic effects. Does not reverse muscle paralysis.</p>
                            </li>
                            <li class="list-item">
                                <strong>Cholinesterase Reactivators: Oximes</strong>
                                <p><strong>Pralidoxime (2-PAM)</strong>: Reactivates phosphorylated ChE enzyme if given early (before "aging" of enzyme). Effective for skeletal muscle paralysis. <strong>Contraindicated in carbamate poisoning.</strong></p>
                            </li>
                        </ol>
                        
                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../../../../../assets/images/image-20251214-c0bb3950.jpeg" alt="Mechanism of ChE inhibition and reactivation" class="figure-image">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 7.2: Reaction of ACh, carbamates, and organophosphates with ChE, and reactivation by oximes.</figcaption>
                        </figure>
                    </div>
                </section>

                <!-- Problem Directed Study -->
                <section class="content-section" id="problem-study">
                    <div class="section-header">
                        <div class="section-number">07</div>
                        <h2 class="section-title">
                            <span class="title-icon">üß©</span>
                            Problem Directed Study
                        </h2>
                    </div>

                    <div class="content-card">
                        <div class="callout callout--warning">
                            <div class="callout-header">
                                <span class="callout-icon">‚ùì</span>
                                <h4 class="callout-title">Case Study 7.1</h4>
                            </div>
                            <div class="callout-content">
                                <p>A man aged 45 years presented with gradual onset complaints of double vision, drooping eyelids, difficulty in chewing food and weakness of limbs which is accentuated by exercise. The symptoms fluctuate in intensity over time. A provisional diagnosis of myasthenia gravis is made.</p>
                                <p><strong>(a) Can a pharmacological test be performed to confirm/refute the diagnosis?</strong></p>
                                <p><strong>(b) In case the diagnosis is confirmed, can this disease be cured by medication?</strong></p>
                                <p><strong>(c) Is there a surgical solution for this illness?</strong></p>
                                <p><em>(See Appendix-1 for solution)</em></p>
                            </div>
                        </div>
                    </div>
                </section>

            </main>

            <nav class="document-nav">
                <div class="nav-container">
                    <a href="topic-07-ans-general.html" class="nav-button nav-button--large nav-button--previous">
                        <div class="nav-label">Previous</div>
                        <div class="nav-title">ANS: General Considerations</div>
                    </a>
                    
                    <div class="document-progress">
                        <div class="progress-indicator">
                            <span>8</span>
                            <span class="progress-separator">/</span>
                            <span>13</span>
                        </div>
                        <div class="progress-bar-container">
                            <div class="progress-bar-fill" style="width: 61.5%;"></div>
                        </div>
                        <div class="progress-label">Topic Progress</div>
                    </div>
                    
                    <a href="topic-09-anticholinergic.html" class="nav-button nav-button--large nav-button--next">
                        <div class="nav-label">Next</div>
                        <div class="nav-title">Anticholinergic Drugs</div>
                    </a>
                </div>
            </nav>
        </article>
    </div>
</div>

<div class="lightbox-modal" id="lightbox-modal" role="dialog" aria-modal="true" aria-label="Image viewer" hidden>
    <div class="lightbox-backdrop"></div>
    <div class="lightbox-content">
        <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
        <img class="lightbox-image" src="" alt="">
        <p class="lightbox-caption"></p>
    </div>
</div>

<script src="../js/theme.js"></script>
<script src="../js/navigation.js"></script>
<script src="../js/interactions.js"></script>
</body>
</html>
